Second-line therapy of erlotinib in advanced non-small cell lung cancer

HAO Ji-qing,QIAN Yong,WU Hong-yang
DOI: https://doi.org/10.3969/j.issn.1009-0460.2009.08.008
2009-01-01
Chinese Clinical Oncology
Abstract:Objective:To evaluate the efficacy and the side effect of erlotinib as the second line therapy in the treatment of patients with advanced non-small cell lung cancer(NSCLC).Methods:Twenty-eight patients with advanced NSCLC were treated with erlotinib which was given orally as a single drug at a dose of 150mg per day.The efficacy was evaluated according to RECIST criteria and the adverse events were evaluated according to NCI criteria.Results:There was no complete response(CR),partial response(PR) 17.86%,stable disease(SD) 42.86%,progressive disease(PD) 39.28%.The response rate(CR+PR) was 17.86%,the disease control rate(CR+PR+SD) was 60.72% in the 28 cases.Time to progression(TTP) was 2-11 months,and median time to progession(mTTP) was 5.7 months.Median survival time(MST) was 11.5 months.The main side effects were rash and itch of skin,diarrhea and nausea,which could be relieved by treatment.Conclusion:It is effective and feasible to treat advanced NSCLC with erlotinib as the second line therapy.
What problem does this paper attempt to address?